Lilly Alimta Favorable Toxicity Outweighs Uncertain Survival Effect, Cmte Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s oncologic drugs advisory committee recommends accelerated approval of Alimta for the treatment of second line non-small cell lung cancer. Alimta results in less neutropenia and other adverse events, committee says.